-+ 0.00%
-+ 0.00%
-+ 0.00%

Oncodesign Precision Medicine completes OPM-201 tablet technical batches ahead of Phase 1b trial

PUBT·10/07/2026 16:00:34
Listen to the news
Oncodesign Precision Medicine completes OPM-201 tablet technical batches ahead of Phase 1b trial
  • Oncodesign Precision Medicine reported manufacturing progress for OPM-201, a Parkinson’s LRRK2 inhibitor, clearing preparations for a Phase 1b trial.
  • Completed API micronization. Produced feasibility and technical tablet batches, including placebo, meeting quality criteria. Finished a CDMO quality audit.
  • EMA CHMP endorsed OPM’s long-term toxicology plan on July 23, 2026, supporting continued clinical development of OPM-201.
  • A GLP toxicology study is slated to start in H1 2027. A comparative metabolism study in human and animal hepatocytes has been completed.
  • PK/PD modeling from Phase 1 data is guiding Phase 1b dose selection. A pre-IND meeting request is being prepared. IND filing is planned for early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncodesign Precision Medicine SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007877096) on October 07, 2026, and is solely responsible for the information contained therein.